Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial
John V. Reynolds, Shaun R. Preston, Brian Patrick O’Neill, et al.
˜The œLancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 11, pp. 1015-1027
Open Access | Times Cited: 91

Showing 1-25 of 91 citing articles:

Advances in diagnosis and management of cancer of the esophagus
Nathaniel Deboever, Christopher M. Jones, Kohei Yamashita, et al.
BMJ (2024), pp. e074962-e074962
Open Access | Times Cited: 35
Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses
Ronan J. Kelly, Blair V. Landon, Ali H. Zaidi, et al.
Nature Medicine (2024) Vol. 30, Iss. 4, pp. 1023-1034
Open Access | Times Cited: 26
Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal Cancer
Jens Hoeppner, Thomas Brunner, Claudia Schmoor, et al.
New England Journal of Medicine (2025) Vol. 392, Iss. 4, pp. 323-335
Closed Access | Times Cited: 5
Oesophageal cancer
Hong Yang, Feng Wang, Christopher L. Hallemeier, et al.
The Lancet (2024) Vol. 404, Iss. 10466, pp. 1991-2005
Closed Access | Times Cited: 14
Metformin in Esophageal Carcinoma: Exploring Molecular Mechanisms and Therapeutic Insights
Stavros P. Papadakos, Alexandra Argyrou, Vasileios Lekakis, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 5, pp. 2978-2978
Open Access | Times Cited: 5
Biomarkers in gastroesophageal cancer 2025: an updated consensus statement by the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP)
María Alsina, Ana Teijo‐Quintans, Míriam Cuatrecasas, et al.
Clinical & Translational Oncology (2025)
Open Access
An Editorial on Salvage Esophagectomy for Esophageal Cancer
B. Feike Kingma
Annals of Surgical Oncology (2025)
Closed Access
Perioperative Therapiekonzepte bei Adenokarzinomen des Ösophagus und des gastroösophagealen Übergangs
Magdalena K. Scheck, Sylvie Lorenzen
Deleted Journal (2025)
Closed Access
Liquid Biopsy and Multidisciplinary Treatment for Esophageal Cancer
Yuki Hoshi, Satoru Matsuda, Masashi Takeuchi, et al.
Cancers (2025) Vol. 17, Iss. 2, pp. 196-196
Open Access
Prognostic factors for patients with esophageal cancer who achieve pathological complete response in the primary tumor after upfront chemotherapy or chemoradiotherapy
Masaaki Motoori, Koji Tanaka, Hiroshi Miyata, et al.
Annals of Gastroenterological Surgery (2025)
Open Access
Real-world outcomes of the CROSS regimen in patients with resectable esophageal or gastro-esophageal junction adenocarcinoma: a nationwide cohort study in the Netherlands
Hanneke W.M. van Laarhoven, Rob H.A. Verhoeven, Mark I. van Berge Henegouwen, et al.
EClinicalMedicine (2025) Vol. 80, pp. 103067-103067
Closed Access
Is it time to retire preoperative radiation for localized esophageal and gastro-esophageal adenocarcinoma?
Cindy M. Pabon, Benjamin Spieler, Jing Li, et al.
The Oncologist (2025) Vol. 30, Iss. 1
Open Access
Actualización del cáncer de esófago
A.M. Jiménez Gordo, Enrique Casado Sáenz, I. Hernández de Córdoba Sánchez, et al.
Medicine - Programa de Formación Médica Continuada Acreditado (2025) Vol. 14, Iss. 25, pp. 1459-1468
Closed Access
Disease-free survival as surrogate for overall survival in esophageal cancer: an individual patient data meta-analysis of neoadjuvant chemotherapy and chemoradiotherapy
Nicolas Cabrit, M. Cheugoua-Zanetsie, Jayne F. Tierney, et al.
European Journal of Cancer (2025) Vol. 218, pp. 115292-115292
Closed Access
The changing landscape of multimodal treatment for locally advanced oesophageal and junctional adenocarcinoma
Sander J. M. van Hootegem, Bas P. L. Wijnhoven, Matteo Pittacolo, et al.
British journal of surgery (2025) Vol. 112, Iss. 2
Closed Access
ESMO Clinical Practice Guideline interim update on the treatment of locally advanced oesophageal and oesophagogastric junction adenocarcinoma and metastatic squamous-cell carcinoma
Radka Obermannová, Trevor Leong
ESMO Open (2025), pp. 104134-104134
Open Access
Surveillance frequency in resected esophageal cancer: towards personalization of follow-up.
Jarlath Bolger, Karren Xiao, Ivan Ristic, et al.
European Journal of Surgical Oncology (2025), pp. 110001-110001
Open Access
Significance of Surgery for Resectable M1 Lymph Node Metastases Without Organ Metastasis in Esophageal Carcinoma in the Era of Neoadjuvant Treatment
Shota Igaue, Ryoko Nozaki, Daichi Utsunomiya, et al.
Annals of Surgical Oncology (2023) Vol. 31, Iss. 3, pp. 1525-1535
Closed Access | Times Cited: 10
The Evolving Landscape of Neoadjuvant Immunotherapy in Gastroesophageal Cancer
Colum Dennehy, Alisha F. Khan, Ali H. Zaidi, et al.
Cancers (2024) Vol. 16, Iss. 2, pp. 286-286
Open Access | Times Cited: 3
Development of a clinical nomogram for prediction of response to neoadjuvant chemotherapy in patients with advanced gastric cancer
Bing Liu, Yu-Jie Xu, Feng-Ran Chu, et al.
World Journal of Gastrointestinal Surgery (2024) Vol. 16, Iss. 2, pp. 396-408
Open Access | Times Cited: 3
Adjuvant Chemotherapy With or Without Radiotherapy for Resected Pancreatic Cancer After Multiagent Neoadjuvant Chemotherapy
Oskar Franklin, Toshitaka Sugawara, Richard B. Ross, et al.
Annals of Surgical Oncology (2024) Vol. 31, Iss. 8, pp. 4966-4975
Closed Access | Times Cited: 3
Prognostic value of Mandard score and nodal status for recurrence patterns and survival after multimodal treatment of oesophageal adenocarcinoma
Sofie Henckens, Dajia Liu, Suzanne S. Gisbertz, et al.
British journal of surgery (2024) Vol. 111, Iss. 2
Open Access | Times Cited: 2
Safety and efficacy of perioperative FLOT regimen in Japanese patients with gastric, esophagogastric junction, or esophageal adenocarcinoma: a single-institution experience
Shogo Takei, Akihito Kawazoe, Amane Jubashi, et al.
ESMO Gastrointestinal Oncology (2024) Vol. 4, pp. 100050-100050
Open Access | Times Cited: 2
Presence of Fusobacterium nucleatum in relation to patient survival and an acidic environment in oesophagogastric junction and gastric cancers
Yoshihiro Hara, Yoshifumi Baba, Eri Oda, et al.
British Journal of Cancer (2024) Vol. 131, Iss. 5, pp. 797-807
Closed Access | Times Cited: 2
SEOM-GEMCAD-TTD clinical guideline for the diagnosis and treatment of gastric cancer (2023)
Fernando Rivera, Federico Longo, Marta Martín Richard, et al.
Clinical & Translational Oncology (2024) Vol. 26, Iss. 11, pp. 2826-2840
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top